SCHEMBL20249295

SCHEMBL20249295

CC(C)(C)c1ccc(N2CC3(CCNC3)C2)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.40
HSD17B10 Q99714 6/20 0.40
CYP1A2 P05177 5/20 0.40
HPGD P15428 4/20 0.40
PIM1 P11309 3/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
TSHR P16473 6/20 0.36
CYP3A4 P08684 7/20 0.35
KCNH2 Q12809 1/20 0.34
CYP2D6 P10635 6/20 0.34
USP2 O75604 4/20 0.34
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 2/20 0.34
BPTF Q12830 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249303 0.92 ALDH1A1 (0.49) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20249284 0.88 BPTF (0.33) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20038231 0.78 CHRNB2 (0.35) BPTF
SCHEMBL20038194 0.78 ALDH1A1 (0.43) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20037714 0.78 ALDH1A1 (0.40) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20249311 0.77 HRH4 (0.33)
SCHEMBL20249248 0.77 TSHR (0.41) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20249336 0.76 CYP11B1 (0.42) CYP11B1
SCHEMBL20255340 0.76 ALDH1A1 (0.34) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20249270 0.74 TRPV1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 ALDH1A1 944/4885HSD17B10 2513/4885CYP1A2 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.